Phio Pharmaceuticals Corp - Asset Resilience Ratio
Phio Pharmaceuticals Corp (PHIO) has an Asset Resilience Ratio of 1.31% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PHIO current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2017)
This chart shows how Phio Pharmaceuticals Corp's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Phio Pharmaceuticals Corp's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Phio Pharmaceuticals Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Phio Pharmaceuticals Corp long-term investment allocation to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $50.00K | 1.31% |
| Total Liquid Assets | $50.00K | 1.31% |
Asset Resilience Insights
- Limited Liquidity: Phio Pharmaceuticals Corp maintains only 1.31% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Phio Pharmaceuticals Corp Industry Peers by Asset Resilience Ratio
Compare Phio Pharmaceuticals Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Phio Pharmaceuticals Corp (2012–2017)
The table below shows the annual Asset Resilience Ratio data for Phio Pharmaceuticals Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 1.22% | $50.00K | $4.10 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $13.40 Million | -- |
| 2015-12-31 | 49.29% | $5.50 Million | $11.16 Million | +48.74pp |
| 2014-12-31 | 0.54% | $50.00K | $9.19 Million | -19.54pp |
| 2013-12-31 | 20.08% | $3.00 Million | $14.94 Million | +19.14pp |
| 2012-12-31 | 0.95% | $53.00K | $5.59 Million | -- |
About Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene ex… Read more